Skip to content

Type VI Secretion System in Klebsiella Pneumoniae

Type VI Secretion System in Klebsiella Pneumoniae Relation to Antibiotic Resistance and Biofilm Formation

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05516654
Acronym
Klebsiella
Enrollment
70
Registered
2022-08-25
Start date
2022-09-10
Completion date
2023-09-30
Last updated
2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Detection of Relation to Ab Resistance, Biofilm, Detection of Type VI Secretion System in K.Pneumoniae

Keywords

Type IV, secretion system, Klebsiella Pneumoniae

Brief summary

Klebsiella pneumoniae (K. pneumoniae) is an important opportunistic pathogen contributing to nosocomial and antimicrobial-resistant infections. The increasing prevalence of infections caused by multidrug-resistant K. pneumoniae has emerged as a major clinical and public health threat, while the serous organ and life-threatening infections caused by highly virulent K. pneumoniae have also emerged( Russo and Marr, 2019; Wyres et al., 2020).

Detailed description

Both drug-resistant and highly virulent K. pneumoniae have brought major challenges to clinical treatment and stimulated interest in studying K. pneumoniae. However, knowledge of the genomics, ecology, and pathogenicity of K. pneumoniae is relatively limited. Recently, the type VI secretion system (T6SS) was identified as a virulence factor in K. pneumoniae (Martin and Bachman, 2018). Furthermore, K. pneumoniae was found to exploit the T6SS nano-weapon to destroy bacterial competitors and fungi (Storey et al., 2020). The bacterial Type VI Secretion System (T6SS) is a membrane-attached contractile phage tail that is physically and Mechanistically similar to a membrane-linked intracellular contractile phage tail. T6SS spike and tube elements, as well as anti-bacterial and anti-eukaryotic effectors, are propelled out of predatory T6SS positive cells and into target cells by a fast conformational shift in the structural framework of a sheath protein complex, according to recent research (Kudryashev et al., 2015). However, the limited studies and lack of information on the T6SS in K. pneumoniae necessitate further exploration to clarify the physiological metabolism and pathogenic information of this clinically important bacterial species.

Interventions

DIAGNOSTIC_TESTRoutine bacteriological cultures

culture of different samples on different culture media as nutrient agar, blood agar, MacConkey agar, EMB agar, TSI

DIAGNOSTIC_TESTIdentification of the organism and antibiotic sensitivity will be done by VITEK II

Automated identification of the organism and antibiotic sensitivity will be done by VITEK II

DIAGNOSTIC_TESTDetection of biofilm formation

Detection of Biofilm formation to the collected organism by tissue culture plate method.

DIAGNOSTIC_TESTMolecular detection by PCR

Molecular detection of Type VI Secretion System genes, capsular serotyping( k1, k2), and FimH genes by PCR.

Sponsors

Sohag University
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
12 Weeks to 90 Years
Healthy volunteers
No

Inclusion criteria

* All patients suffering from infections that can be caused by Klebsiella Pneumoniae.

Exclusion criteria

* Samples diagnosed to have organisms other than Klebsiella Pneumoniae

Design outcomes

Primary

MeasureTime frame
Isolation and identification of Klebsiella Pneumoniae isolated from different samples and determination of their antibiotics profile1 september 2022 to 1 November 2022
Detection of Type VI Secretion System In Klebsiella Pneumoniae and its relation to Antibiotic Resistance and biofilm formation2 November 2022 to February 2023

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026